Kyprolis carfilzomib: Phase II data

Researchers at the University of Torino reported data from an open-label, European Phase II trial in 58 patients with newly diagnosed MM showing that IV Kyprolis plus cyclophosphamide and dexamethasone led a 2-year PFS rate of 76% and a 2-year OS rate of 87% at a median follow-up of 18.1 months. Additionally, 77% of patients achieved a very good partial response or better and 64% of patients achieved at least a near complete response after 9 cycles of treatment. Patients received induction therapy every 28 days for 9 cycles with 20 mg/m 2 Kyprolis on days 1 and 2 and 36 mg/m 2 on days 8, 9, 15 and 16 of cycle 1 and 36 mg/m 2 on days 1, 2, 8, 9, 15, and 16 of cycles 2-9 plus 300 mg/m 2 cyclophosphamide on days 1, 8 and 15 and 40 mg dexamethasone on days 1, 8, 15 and 22 of each cycle. Maintenance therapy consisted of 36 mg/m 2 Kyprolis on days 1, 2, 15 and 16 every 28 days until progression or intolerance. Data were presented at the American Society of Hematology meeting in New Orleans. Amgen could not be reached for next steps with Kyprolis in newly diagnosed MM. ...